Skip to content

Therapeutic effect of Tekodigest capsule in dyspepsia

Comparative efficacy of Tekodigest capsule versus Omeprazole in patients with functional dyspepsia: A randomized, double-blind, non-inferiority clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251014067618N2
Enrollment
154
Registered
2026-01-26
Start date
2026-01-25
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional dyspepsia. Functional dyspepsia

Interventions

Intervention 1: Intervention group: Participants in the intervention group will receive Tekodigest softgel ( 250 mg pistacia atlantica gum essential oil and 500 mg black seed oil) twice daily for 28 d

Sponsors

Sanandaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Functional dyspepsia Age between 18-65 Prescription of ppi Willing to participate in the study

Exclusion criteria

Exclusion criteria: History of peptic ulcer Presence of alarm sign Infection with Helicobacter pylori History of upper digestive tract surgery Presence of gastro-esophagus reflux Presence of Biliary disorders Presence of peptic ulcer or digestive tract bleeding Current Helicobacter pylori eradication regimen Severe and chronic digestive, pulmonary or renal disorders Patients with IBS syndrome History of antibiotics consumption in last four weeks Current consumption of medicines that have effect on digestive tract such as antacids, laxatives, aspirin, NSAIDS, herbal medicines in last two weeks Pregnant or breastfeeding women Sensitivity or allergy to any components of the herbal capsule

Design outcomes

Primary

MeasureTime frame
Dyspepsia symptoms severity. Timepoint: Measurement of dyspepsia severity at baseline (before the start of the intervention) and 28 days after treatment. Method of measurement: Total dyspepsia symptom scale.;Percentage of healing. Timepoint: 28 days after start of treatment. Method of measurement: Total dyspepsia symptom scale.

Secondary

MeasureTime frame
Recurrence of symptoms. Timepoint: 28 days after end of intervention. Method of measurement: Total dyspepsia symptom scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarshad Sheikh Esmaeili

Sanandaj University of Medical Sciences

dr_s_smaili@yahoo.com+98 87 3366 4645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026